Secondary dyslipidemia: its treatments and association with atherosclerosis

被引:37
|
作者
Yanai, Hidekatsu [1 ]
Yoshida, Hiroshi [2 ]
机构
[1] Kohnodai Hosp, Dept Diabet Endocrinol & Metab, Natl Ctr Global Hlth & Med, 1-7-1 Kohnodai, Chiba 2728516, Japan
[2] Jikei Univ, Dept Lab Med, Kashiwa Hosp, Chiba, Japan
来源
GLOBAL HEALTH & MEDICINE | 2021年 / 3卷 / 01期
关键词
hypothyroidism; low-density lipoprotein; nephrotic syndrome; triglyceride;
D O I
10.35772/ghm.2020.01078
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Dyslipidemia is classified into primary and secondary types. Primary dyslipidemia is basically inherited and caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and cholesterol. Secondary dyslipidemia is caused by unhealthy lifestyle factors and acquired medical conditions, including underlying diseases and applied drugs. Secondary dyslipidemia accounts for approximately 30-40% of all dyslipidemia. Secondary dyslipidemia should be treated by finding and addressing its causative diseases or drugs. For example, treatment of secondary dyslipidemia, such as hyperlipidemia due to hypothyroidism, by using statin without controlling hypothyroidism, may lead to myopathy and serious adverse events such as rhabdomyolysis. Differential diagnosis of secondary dyslipidemia is very important for safe and effective treatment. Here, we describe an overview about diseases and drugs that interfere with lipid metabolism leading to secondary dyslipidemia. Further, we show the association of each secondary dyslipidemia with atherosclerosis and the treatments for such dyslipidemia.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [1] Atherosclerosis markers in patients with rheumatoid arthritis: Association with dyslipidemia
    Bass, Valentyna G.
    Stanislavchuk, Mykola A.
    Parkhonyuk, Valeriy P.
    RHEUMATOLOGY, 2008, 47 : II104 - II104
  • [2] Dyslipidemia as a risk factor of cerebral atherosclerosis and the target for secondary prevention
    Lypovetsky, BM
    Churakov, GA
    ATHEROSCLEROSIS, 1999, 144 : 180 - 180
  • [3] Development of Dyslipidemia in Atherosclerosis and Modern Approaches to its Treatment
    Blagov, Alexander
    Sobenin, Igor
    Sukhorukov, Vasily
    Glanz, Victor
    Pleshko, Elizaveta
    Orekhov, Alexander
    HEART SURGERY FORUM, 2024, 27 (06): : E680 - E688
  • [4] Arterial Stiffness and its Association with Dyslipidemia
    Razman, M. R.
    Jamaluddin, A. R.
    Ellyda, M. N.
    Seikh, F. A.
    INTERNATIONAL MEDICAL JOURNAL MALAYSIA, 2013, 12 (02) : 59 - 66
  • [5] DIABETIC DYSLIPIDEMIA AND ATHEROSCLEROSIS
    SHEPHERD, J
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1994, 124 (44) : 1933 - 1937
  • [6] Dyslipidemia and its association with meibomian gland dysfunction
    Braich, Puneet S.
    Howard, Mary K.
    Singh, Jorawer S.
    INTERNATIONAL OPHTHALMOLOGY, 2016, 36 (04) : 469 - 476
  • [7] Dyslipidemia and its association with meibomian gland dysfunction
    Puneet S. Braich
    Mary K. Howard
    Jorawer S. Singh
    International Ophthalmology, 2016, 36 : 469 - 476
  • [8] Migraine frequency and its association with dyslipidemia in women
    Janoska, Marlena
    Chorazka, Kamil
    Domitrz, Izabela
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2015, 49 (02) : 95 - 98
  • [9] DYSLIPIDEMIA AND ACCELERATED ATHEROSCLEROSIS
    HAZZARD, WR
    HOSPITAL PRACTICE, 1988, 23 (5A): : 41 - 50
  • [10] Dyslipidemia and its association with cytokines in patients with SLE
    Sitko, Jan
    Stanislava, Blazickova
    Zuzana, Bardyova
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 66 - 66